Deerfield Management ADMA Position
Exited3-Fund ConvergenceDeerfield Management exited their position in ADMA Biologics Inc. (ADMA) in Q4 2024, after holding the stock for 5 quarters.
The position was first reported in Q4 2023 and has been tracked across 5 quarterly 13F filings.
ADMA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 13.3% of float with 7.2 days to cover, indicating significant bearish positioning against the stock.
About ADMA Biologics Inc.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Full company profile →Short Interest
13.3%
7.2 days to cover
Deerfield Management ADMA Position History
Frequently Asked Questions
Does Deerfield Management own ADMA?
No. Deerfield Management exited their position in ADMA Biologics Inc. (ADMA) in Q4 2024. They previously held the stock for 5 quarters.
How many hedge funds own ADMA?
3 specialist biotech hedge funds currently hold ADMA, including Driehaus Capital, Perceptive Advisors, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ADMA?
Deerfield Management's position in ADMA was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ADMA position increasing or decreasing?
Deerfield Management completely exited their ADMA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ADMACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →